Intellikine has initiated a multicentre Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.

INK1117 is a selective, orally available, small molecule inhibitor of the PI3Kalpha isoform.

The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetic profile of the PI3Kalpha selective inhibitor.

In PI3Kalpha mutant-specific preclinical tumour models, INK1117 has demonstrated good efficacy results.

Vall d’Hebron University Hospital, Barcelona, Medical Oncology Department head Josep Tabernero said they will explore INK1117 in cancer patients, particularly those whose tumours have a mutation of the PIK3CA gene.